No association between p73 G4C14-to-A4T14 polymorphism and the risk of lung cancer in a Korean population

Biochemical Genetics

Volumn 44, Issue 11-12, 2006, Pages 533-540

  Choi, Jin Eun ^a   Kang, Hyo Gyoung ^a   Chae, Myung Hwa ^a   Kim, Eun Jin ^a   Lee, Won Kee ^b   Cha, Sung Ick ^a   Kim, Chang Ho ^a   Jung, Tae Hoon ^a   Park, Jae Yong ^a  

^a Kyungpook National University Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

Genetic susceptibility; Lung cancer; p73; Polymorphism

Indexed keywords

PROTEIN P73;

ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONFIDENCE INTERVAL; GENDER; GENE; GENOTYPE; HUMAN; KOREA; LUNG CANCER; POPULATION; PROTEIN POLYMORPHISM;

EID: 33845906111     PISSN: 00062928     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10528-006-9056-8     Document Type: Article

References (33)

1. Casciano, I., Mazzocco, K., Boni, L., Pagnan, G., Banelli, B., Allemanni, G., Ponzoni, M., Tonini, G. P., and Romani, M. (2002). Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 9:246.
2. Davis, P. K., and Dowdy, S. F. (2001). p73. Int. J. Biochem. Cell Biol. 33:935.
3. Garcia-Closas, M., Rothman, N., and Lubin, J. (1999). Misclassification in case-control studies of gene-environment interactions: Assessment of bias and sample size. Cancer Epidemiol. Biomarkers Prev. 8:1043.
4. Hecht, S. S. (2002). Cigarette smoking and lung cancer: Chemical mechanisms and approaches to prevention. Lancet Oncol. 3:461.
5. Hiraki, A., Matsuo, K., Hamajima, N., Ito, H., Hatooka, S., Suyama, M., Mitsudomi, T., and Tajima, K. (2003). Different risk relations with smoking for non-small cell lung cancer: Comparison of TP53 and TP73 genotypes. Asian Pac. J. Cancer Prev. 4:107.
6. Hu, Z., Miao, X., Ma, H., Tan, W., Wang, X., Lu, D., Wei, Q., Lin, D., and Shen, H. (2005). Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int. J. Cancer 114:455.
7. Ikawa, S., Nakagawara, A., and Ikawa, Y. (1999). p53 family genes: Structural comparison, expression and mutations. Cell Death Differ. 6:1154.
8. Kaelin, W. G. (1999). The emerging p53 gene family. J. Natl. Cancer Inst. 91:594.
9. Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J. C., Valent, A., Minty, A., Chalon, P., Lelias, J. M., Dumont, X., Ferrara, P., McKeon, F., and Caput, D. (1997). Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809.
10. Lee, C. T., Kang, K. H., Koh, Y., Chang, J., Chung, H. S., Park, S. K., Yoo, K. Y., and Song, J. S. (2000). Characteristics of lung cancer in Korea, 1997. Lung Cancer 30:15.
11. Lee, S. J., Jeon, H. S., Jang, J. S., Park, S. H., Lee, G. Y., Lee, B. H., Kim, C. H., Kang, Y. M., Lee, W. K., Kam, S., Park, R. W., Kim, I. S., Cho, Y. L., Jung, T. H., and Park, J. Y. (2005a). DNMT3B polymorphisms and risk of primary lung cancer. Carcinogenesis 26:403.
12. Lee, S. J., Lee, S. Y., Jeon, H. S., Park, S. H., Jang, J. S., Lee, G. Y., Son, J. W., Kim, C. H., Lee, W. K., Kam, S., Park, R. W., Park, T. I., Kang, Y. M., Kim, I. S., Jung, T. H., and Park, J. Y. (2005b). Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol. Biomarkers Prev. 14:571.
13. Levrero, M., De Kaurenzi, V., Costanzo, A., Sabatini, S., Gong, J., Wang, J. Y. J., and Melino, G. (2000). The p53/p63/p73 family of transcription factors: Overlapping and distinct functions. J. Cell Sci. 113:1661.
14. Li, G., Sturgis, E., Wang, L. E., Chamberlain, R. M., Amos, C. I., Spitz, M. R., El-Naggar, A. K., Hong, W. K., and Wei, Q. (2004a). Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with the risk of squamous cell carcinoma of the head and neck. Carcinogenesis 25:1911.
15. Li, G., Wang, L. E., Chamberlain, R. M., Amos, C. I., Spitz, M. R., and Wei, Q. (2004b). p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res. 64:6863.
16. Li, Q., Athan, E. S., Wei, M., Yuan, E., Rice, S. L., Vonsattel, J. P., Mayeux, R. P., and Tycko, B. (2004). TP73 allelic expression in human brain and allele frequencies in Alzheimer's disease. BMC Med. Genet. 5:14.
17. Mai, M., Yokomizo, A., Qian, C., Yang, P., Tindall, D. J., Smith, D. I., and Liu, W. (1998). Activation of p73 silent allele in lung cancer. Cancer Res. 58:2347.
18. Moll, U. M., and Slade, N. (2004). p63 and p73: Roles in development and tumor formation. Mol. Cancer Res. 2:371.
19. Niwa, Y., Hirose, K., Matsuo, K., Yamamoto, K., Tamakoshi, A., Saito, T., Hirose, K., Nakanishi, T., Nawa, A., Kuzuya, K., and Tajima, K. (2005). Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett. 219:183.
20. Nomoto, S., Haruki, N., Kondo, M., Konishi, H., Takahashi, T., Takahashi, T., and Takahashi, T. (1998). Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res. 58:1380.
21. Peters, M. A., Janer, M., Kolb, S., Jarvik, G. P., Ostrander, E. A., and Standford, J. L. (2001). Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer. Prostate 48:292.
22. Pozniak, C. D., Radinovic, S., Yang, A., McKeon, F., Kaplan, D. R., and Miller, F. D. (2000). An anti-apoptotic role of the p53 family member, p73, during developmental neuron death. Science 289:304.
23. Ryan, B. M., McManus, R., Daly, J. S., Carton, E., Keeling, P. W. N., Reynolds, J. V., and Kelleher, D. (2001). A common p73 polymorphism is associated with a reduced incidence of esophageal carcinoma. Br. J. Cancer 85:1499.
24. Sellers, T. A., Bailey-Wilson, J. E., Potter, J. D., Rich, S. S., Rothschild, H., and Elston, R. C. (1992). Effect of cohort differences in smoking prevalence on models of lung cancer susceptibility. Genet. Epidemiol. 9:261.
25. Shields, P. G., and Harris, C. C. (2000). Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J. Clin. Oncol. 18:2309.
26. Spitz, M. R., Wei, Q., Dong, Q., Amos, C. I., and Wu, X. (2003). Genetic susceptibility to lung cancer: The role of DNA damage and repair. Cancer Epidemiol. Biomarkers Prev. 12:689.
27. Stiewe, T., Zimmermann, S., Frilling, A., Esche, H., and Putzer, B. M. (2002). Transactivation deficient ΔTA-73 acts as an oncogene. Cancer Res. 62:3598.
28. Sun, T., Miao, X., Zhang, X., Tan, W., Xiong, P., and Lin, D. (2004). Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J. Natl. Cancer Inst. 96:1030.
29. Tokuchi, Y., Hashimoto, T., Kobayashi, Y., Hayashi, M., Nishida, K., Hayashi, S., Imai, K., Nakachi, K., Ishigawa, Y., Nakagawa, K., Kawakami, Y., and Tsuchiya, E. (1999). The expression of p73 is increased in lung cancer, independent of p53 gene alteration. Br. J. Cancer 80:1623.
30. Yang, A., Walker, N., and Bronson, R. (2000). p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumors. Nature 404:99.
31. Yokomizo, A., Mai, M., Tindall, D. J., Cheng, L., Bostwick, D. G., Naito, S., Smith, D. I., and Liu, W. (1999). Overexpression of the wild type p73 gene in human bladder cancer. Oncogene 18:1629.
32. Zaika, A. I., Kovalev, S., Marchenko, N. D., and Moll, U. M. (1999). Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res. 59:3257.
33. Zaika, A. I., Slade, N., Erster, S. H., Sansome, C., Joseph, T. W., Pearl, M., Chalas, E., and Moll, U. M. (2002). ΔNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is upregulated in ovarian cancer. J. Exp. Med. 196:765.